1001 The impact of re-TUR on clinical outcomes in a large cohort of t1g3 patients treated with BCG

Gontero, Paolo; Sylvester, R.; Pisano, Francesca; Joniau, Steven; Eeckt, Kathy Vander; Serretta, Vincenzo; Larré, S.; Stasi, S. Di; Rhijn, Bas van; Witjes, Alfred; Grotenhuis, Anne J.; Kiemeney, Bart; Colombo, Roberto; Briganti, Alberto; Babjuk, M.; Soukup, Viktor; Malmström, Per Uno; Irani, J.; Malats, Nuria; Baniel, Jack; Cai, Truel; Cha, Elva; Ardelt, Petere; Varkarakis, John; Bartoletti, Riccardo; Sphan, Martin; Dalbagni, Guido; Shariat, Shahrokh F.; Xylinas, E.; Karnes, J.; Palou, Joan

doi:10.1016/s1569-9056(14)60984-2

Cited by 6 publications

(6 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Macroscopically complete resection of bladder tumours, as well as the presence of muscle in the specimens was confirmed in all cases in order to be included in the study. Recently, Gontero et al [37] showed, in a cohort of 2530 primary T1G3, that re-TUR in the presence of muscle in the primary specimen does not improve the outcome for recurrence-, progression-, and cancer-specific survival after adjusting for prognostic factors. Moreover, the relatively low short-and intermediate-term recurrence and progression rates supported the validity of our data.…”

Section: Discussionmentioning

confidence: 99%

Is it possible to stop follow-up of patients with primary T1G3 urothelial carcinoma of the bladder managed with intravesical bacille Calmette–Guérin immunotherapy?

Golabek¹,

Palou

Rodríguez

et al. 2016

World J Urol

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Is it possible to stop follow-up of patients with primary T1G3 urothelial carcinoma of the bladder managed with intravesical bacille Calmette–Guérin immunotherapy?

Golabek¹,

Palou

Rodríguez

et al. 2016

World J Urol

View full text Add to dashboard Cite

show abstract

“…2 Although other authors found a lower incidence and much lower understaging, they already advocated re-TURBT practice more selectively. 34 Recently, Gontero et al 35 in a series of more than 2500 patients with urothelial carcinoma T1G3 have confirmed that the re-TURBT only had a positive impact on recurrence, progression, and overall survival if there was no representation of muscle in the initial piece of TUR.…”

Section: Discussionmentioning

confidence: 97%

Retrospective study of various conservative treatment options with bacille Calmette-Guérin in bladder urothelial carcinoma T1G3: Maintenance therapy

Palou-Redorta

Solsona²,

Angulo

et al. 2016

Actas Urológicas Españolas (English Edition)

View full text Add to dashboard Cite

“…Both randomised trials and population-based data have confirmed the beneficial effect of SLR on recurrence, progression and death from bladder cancer [4][5][6]. Recently, however, a large retrospective study found no effect of SLR on recurrence, progression or death from bladder cancer if detrusor muscle was present at the primary resection [7].…”

Section: Definitionsmentioning

confidence: 95%

“…Furthermore, RV and RTV might be used as markers to monitor the quality of the TUR to improve treatment outcome. therefore we could not study this important factor for tumour recurrence and progression as has previously been done in many investigations [1][2][3][4][5][6][7]. However, provided detrusor muscle is present in the TUR specimen, SLR might not be necessary [7].…”

Section: The Quality Of the Primary Resectionmentioning

confidence: 98%

The Resected Tumour Volume of the Specimen as a Marker of the Quality of the Transurethral Resection in T1 Urinary Bladder Cancer

Jahnson¹,

Olsson²

2019

Int J Cancer Clin Res

View full text Add to dashboard Cite

Objective: To study the resected volume (RV) and the resected tumour volume (RTV) in the microscopic examination of the TUR specimen in relation to tumour size, clinical variables and outcome. Materials and methods: This prospectively performed population-based study included all patients in the Southeast Healthcare Region in Sweden with T1 UBC registered in the period 1992-2001, inclusive. RV, RTV and important clinic-pathological variables were studied. All patients had T1 tumours including detrusor muscle at the histopathological examination. Median values for RV and RTV were cutoff points for dichotomisation and 3 cm was the cutoff point for tumour size measured at TUR. Recurrence and progression were analysed using Kaplan-Meier curves with Log-rank test and Cox Proportional Hazards analysis. Results: Out of 211 patients we observed low RV in 112 (53%), low RTV in 113 (54%) and tumour size > 3 cm in 109 (52%). Patients with tumour size > 3 cm and low RV had shorter time to recurrence and progression compared to those with high RV (p = 0.006 and p = 0.087, respectively) and this was also the case when comparing patients with low RTV versus high RTV (p < 0.001 and p = 0.017, respectively). Conclusions: Patients with tumours > 3 cm and low RV or low RTV at TUR for T1 UBC are at higher risk for recurrence or progression, indicating an insufficient TUR. Extensive SLR is particularly important for these patients. RV and RTV might also be used as markers to monitor the quality of the TUR to improve treatment outcome.

show abstract

1001 The impact of re-TUR on clinical outcomes in a large cohort of t1g3 patients treated with BCG

Cited by 6 publications

References 0 publications

Is it possible to stop follow-up of patients with primary T1G3 urothelial carcinoma of the bladder managed with intravesical bacille Calmette–Guérin immunotherapy?

Is it possible to stop follow-up of patients with primary T1G3 urothelial carcinoma of the bladder managed with intravesical bacille Calmette–Guérin immunotherapy?

Retrospective study of various conservative treatment options with bacille Calmette-Guérin in bladder urothelial carcinoma T1G3: Maintenance therapy

The Resected Tumour Volume of the Specimen as a Marker of the Quality of the Transurethral Resection in T1 Urinary Bladder Cancer

Contact Info

Product

Resources

About